Clinical Trial Shows electroCore’s Non Invasive Vagus Nerve Stimulation Therapy Is Effective In Reducing Cluster Headaches

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BASKING RIDGE, New Jersey--(BUSINESS WIRE)--In a multi-center, randomized, trial across Europe, electroCore’s non-invasive vagus nerve stimulation (nVNS) therapy was found to meet its primary endpoint of statistical significance in reducing the number of cluster headache attacks when compared with the standard of care1. During weeks three and four following the beginning of therapy, the number of cluster headache attacks per week was reduced by 46.3% in patients treated with nVNS compared with 12.5% (p=0.002) in patients treated with the best available standard of care.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC